Compare FTLF & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | CGTX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 79.6M |
| IPO Year | 2006 | 2021 |
| Metric | FTLF | CGTX |
|---|---|---|
| Price | $8.08 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.50 | $3.33 |
| AVG Volume (30 Days) | 12.7K | ★ 467.9K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $21,744,000.00 | N/A |
| Revenue This Year | $30.00 | N/A |
| Revenue Next Year | $6.35 | N/A |
| P/E Ratio | $21.32 | ★ N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $7.66 | $0.55 |
| 52 Week High | $19.95 | $1.83 |
| Indicator | FTLF | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 35.25 |
| Support Level | $8.05 | $0.55 |
| Resistance Level | $9.76 | $1.18 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 43.59 | 37.33 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Dr. Tobias, MusclePharm, Irwin Naturals, Applied Nutrition, Isatori, and Nature's Secret brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).